Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mivavotinib - Takeda Oncology

Drug Profile

Mivavotinib - Takeda Oncology

Alternative Names: CB-659; TAK-659

Latest Information Update: 11 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium
  • Developer Children's Cancer Research Institute; National Cancer Institute (USA); Northwestern University; RTI International; Takeda Oncology
  • Class Amines; Antineoplastics; Cyclohexanes; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Acute myeloid leukaemia
  • Preclinical Lymphoid leukaemia
  • No development reported Gastric cancer; Head and neck cancer; Lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 04 Apr 2023 Calithera Biosciences terminates a phase II trial in diffuse large B-Cell lymphoma in the US as per the sponsors decision (NCT05319028)
  • 10 Jun 2022 Phase-II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater, In adults, In the elderly) in USA (PO) (NCT05319028)
  • 31 Mar 2022 Preclinical pharmacodynamic data in Diffuse large B cell lymphoma released by Calithera
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top